ES2074268T3 - Vacunacion idiotipica contra el linfoma de celulas b. - Google Patents

Vacunacion idiotipica contra el linfoma de celulas b.

Info

Publication number
ES2074268T3
ES2074268T3 ES91905685T ES91905685T ES2074268T3 ES 2074268 T3 ES2074268 T3 ES 2074268T3 ES 91905685 T ES91905685 T ES 91905685T ES 91905685 T ES91905685 T ES 91905685T ES 2074268 T3 ES2074268 T3 ES 2074268T3
Authority
ES
Spain
Prior art keywords
dendritic cells
idiotype
idiotipic
conformation
cell lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905685T
Other languages
English (en)
Inventor
Heribert Bohlen
Jacques Urbain
Camp Benjamin Van
Kristiaan Thielemans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Original Assignee
Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp filed Critical Immune Response Corp
Application granted granted Critical
Publication of ES2074268T3 publication Critical patent/ES2074268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SUMINISTRA UN METODO DE INDUCIR UNA RESPUESTA INMUNE EFECTIVA A LOS LINFOCITOS PATOGENICOS MEDIANTE LA ADMINISTRACION DE CELULAS DENDRITICAS PREVIAMENTE IMPULSADAS CON LA PROTEINA DEL IDIOTIPO DE INTERES. EN UNA CONFORMACION, SE SUMINISTRA UN METODO PARA LA INMUNIZACION ACTIVA DE UN MAMIFERO CONTRA EL LINFOMA. ESTA CONFORMACION COMPRENDE LA EXPOSICION DE LAS CELULAS DENDRITICAS AL IDIOTIPO IG PARA CONSEGUIR CELULAS DENDRITICAS IMPULSADAS CON EL IDIOTIPO E INYECTAR LAS CELULAS DENDRITICAS IMPULSADAS CON EL IDIOTIPO DE NUEVO EN EL MAMIFERO, MEDIANTE LO CUAL SE INDUCE LA INMUNIDAD CONTRA LAS CELULAS DEL LINFOMA. EN OTRA CONFORMACION, LA INVENCION SE REFIERE A LA ADMINISTRACION TANTO DE CELULAS IDIOTIPICAS COMO DE CELULAS DENDRITICAS.
ES91905685T 1990-03-14 1991-03-13 Vacunacion idiotipica contra el linfoma de celulas b. Expired - Lifetime ES2074268T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma

Publications (1)

Publication Number Publication Date
ES2074268T3 true ES2074268T3 (es) 1995-09-01

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905685T Expired - Lifetime ES2074268T3 (es) 1990-03-14 1991-03-13 Vacunacion idiotipica contra el linfoma de celulas b.

Country Status (12)

Country Link
US (1) US20030072751A1 (es)
EP (1) EP0521897B1 (es)
JP (1) JP2735947B2 (es)
AT (1) ATE124265T1 (es)
AU (1) AU645552B2 (es)
CA (1) CA2078235C (es)
DE (1) DE69110877T2 (es)
DK (1) DK0521897T3 (es)
ES (1) ES2074268T3 (es)
FI (1) FI105452B (es)
NO (1) NO308509B1 (es)
WO (1) WO1991013632A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
EP0651653B1 (en) * 1992-07-22 2004-03-10 The Trustees Of Princeton University p53 VACCINE
JPH08503603A (ja) * 1992-08-21 1996-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ 新規のｂリンパ腫細胞株および抗原
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
PT765386E (pt) * 1994-06-14 2015-02-06 Univ Leland Stanford Junior Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
EP1176986B1 (en) 1999-04-20 2018-07-04 Yale University Differentiation of monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
AU645552B2 (en) 1994-01-20
NO923542D0 (no) 1992-09-11
JPH05507905A (ja) 1993-11-11
DE69110877D1 (de) 1995-08-03
NO923542L (no) 1992-09-11
CA2078235A1 (en) 1991-09-15
AU7488691A (en) 1991-10-10
FI924082A0 (fi) 1992-09-11
FI924082L (fi) 1992-09-11
WO1991013632A1 (en) 1991-09-19
ATE124265T1 (de) 1995-07-15
JP2735947B2 (ja) 1998-04-02
FI105452B (fi) 2000-08-31
CA2078235C (en) 2004-01-20
EP0521897A1 (en) 1993-01-13
EP0521897B1 (en) 1995-06-28
DK0521897T3 (da) 1995-11-13
US20030072751A1 (en) 2003-04-17
DE69110877T2 (de) 1995-11-16
NO308509B1 (no) 2000-09-25

Similar Documents

Publication Publication Date Title
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
GR1000039B (el) Ενεργος ειδικη ανοσοαναστολη.
CY1106437T1 (el) Κατασταλτικα κυτταρα για την προληψη και θepαπεια των ανοσοαποκρισεων σε μεταμοσχευση
ES2075327T3 (es) Metodo para multiplicar linfocitos de sangre periferica humana in vitro que producen anticuerpos monoclonales especificos para un antigeno.
ES2017187A6 (es) Electrodo de iontoforesis.
AR029839A1 (es) Metodos para evitar el reconocimiento del reovirus para el tratamiento de trastornos proliferativos celulares
ES2085983T3 (es) Antagonistas de anticuerpos de la interleuquina-4 humana.
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2091684T3 (es) Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
ES2169105T3 (es) Agentes antitromboticos tripeptidicos.
PT1003553E (pt) Utilizacao de esteroides angioestaticos na terapia fotodinamica
ES2179105T3 (es) Adyuvantes proteinicos.
ES2144424T3 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
AR010754A1 (es) Un metodo para prevenir cataratas secundarias en el ojo de un sujeto; y una composicion farmaceutica para aplicar en dicho metodo
ES2166770T3 (es) Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos.
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
IT8719331A0 (it) Mandrino per il fissaggio di cella per la centrifugazione del sangue, e simili.
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
ES2106032T3 (es) Vacuna para inmunizar gatos contra el desprendimiento de oocistos de toxoplasma.
ES2063574T3 (es) Metodo de tratamiento mejorado para el cancer.
ES8707296A1 (es) Un metodo para producir anticuerpos monoclonales humanos
BR9808878A (pt) Imunização contra moléculas endógenas
DE69835615D1 (de) Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521897

Country of ref document: ES